Another potential factor, he adds, is that the disease is seen as a major battle. Since the war on cancer was declared in the 1970s, there has been a major investment in research, with both patients and physicians seemingly more engaged in fighting the disease.
"A large number of cancer specialists are looking over each others' shoulders," he says.
Indeed, Schneider points to the level of attention devoted to cancer as a way of improving the current health care mess. The Rand team blames a "fragmented and chaotic" system that makes it hard to deliver quality service for many chronic conditions. Specialized cancer centers, which bring together different doctors and nurses to treat patients, are growing more commonplace and may offer a model for other diseases.
"It's a team effort," Schneider explains, adding that such coordination can lead to better quality care for the patient.
Still, the one dark cloud on the horizon is the increasing expense of cancer treatments. In a recent speech to business leaders, Dr. Scott Gottleib of the Food and Drug Administration said that cancer costs might be brought under control if new therapies are developed more quickly and at a lower price.
"But right now, the opposite is happening," he said at the Annual Cancer Progress Conference, held in New York. The number of new drugs has reached a twenty-year low, while the overall costs of treating cancer have skyrocketed to more the $156 billion a year. "That's an astonishing figure," said Gottleib, pointing out that the expense is larger than the "gross domestic product of all but a few nations."
"It's hard to predict what will happen with financing cancer care," says Schneider. "Everyone is struggling with higher medical costs."